The European genomics biomarker market is estimated to grow significantly at a CAGR of more than 14% during the forecast period. Factors that are contributing significantly to the market growth include the presence of a well-developed healthcare sector and considerably high healthcare expenditure and infrastructure in its economies such as Germany, UK, France, and others. Other factors contributing to the European genomics biomarker market include the rising prevalence of chronic diseases such as heart disease, cancer, diabetes, stroke, and arthritis. Unhealthy lifestyle such as smoking, consumption of drugs and alcohol in European countries are the major factors for increasing cancer incidences among men and women. Government initiatives, programs, and funding related to increasing awareness of cancer are also contributing to the growth of the market in the region.
To Request a Sample of our Report on European Genomic Biomarker Market: https://www.omrglobal.com/request-sample/european-genomic-biomarkers-market
The European genomic biomarker market is segmented on the basis of application and end-user. On the basis of application, the market is segmented into oncology, cardiology, neurology, and others. There is a huge scope for the market in the oncology segment due to the increasing prevalence of cancer. On the basis of end-user, the market is segmented into hospitals and diagnostic. Further, the report covers the country-level analysis of the genomics biomarker market in Europe. The major economies covered in the report include UK, Germany, Italy, Spain, France, and the Rest of Europe. The rest of Europe is estimated to hold a significant share in the market owing to the increasing healthcare spending in countries such as the Netherlands and Poland. As a result, it is primarily contributing to the adoption of advanced biomarkers for screening and detection of disease and thereby enabling the demand for genomic biomarkers. Moreover, Germany, UK, and Spain are estimated to grow at a considerable CAGR during the forecast period. The significant prevalence of CVD and cancer is expected to propel the adoption of the genomic biomarker in these countries.
(Get 15% Discount on Buying this Report)
A full Report of European Genomic Biomarker Market is Available at: https://www.omrglobal.com/industry-reports/european-genomic-biomarkers-market
European Genomic Biomarker Market Segmentation
By Application
- Oncology
- Cardiology
- Neurology
- Others
By End-User
- Hospitals
- Diagnostic & Research Laboratories
Regional Analysis
- UK
- Germany
- Italy
- Spain
- France
Rest of Europe
Company Profiles
- Abcodia Ltd.
- Acobiom SAS
- Agendia N.V.
- Agilent Technologies, Inc.
- Avacta Group Plc
- Bayer AG
- BioMérieux S.A.
- BioPorto Diagnostics A/S
- Bio-Rad Laboratories, Inc.
- DestiNA Genomics Ltd.
- DNAVision SA
- Eagle Genomics Ltd.
- Epigenomics AG
- Epistem Ltd
- Eurofins Scientific SE
- Evotec AG
- F-Hoffman-La Roche Ltd.
- IntegraGen SA
- Merck KGaA
- Novartis AG
- Qiagen N.V.
- Valirx PLC
- The Almac Group
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
